Serena Williams is opening up about her fitness journey, revealing that she uses the injectable GLP-1 weight loss drug ...

Serena Williams reveals her use of GLP-1, Zepbound and calls out the stigma surrounding the use of the popular weight loss drug.

Serena Williams has been taking a GLP-1 medication to help with her recent weight loss, she revealed for the first time in an ...

For reasons that remain unclear, kidney cancer risk was higher in users of GLP-1 agonists, particularly those under 65 and those who were overweight versus obese.< Patients taking GLP-1 agonists for ...

With 23 Grand Slam singles titles and four Olympic gold medals, Serena Williams is undeniably a superathlete. But the 43-year ...

Everyone is allowed to have their own opinion. But it’s important for me to own my own narrative and tell my own story.” ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

GLP-1 receptor agonists may reduce cancer risk among people with obesity or overweight, according to retrospective study results.Adults who used GLP-1 medications exhibited a statistically significant ...

Columnist Teri Sforza writes that studies have found that semaglutide reduced alcohol intake, binge drinking and relapse ...

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of ...

GLP-1 receptor agonists may outperform metformin in lowering the risk for dementia, particularly Alzheimer’s disease and other nonvascular types, in patients with type 2 diabetes.

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...